These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37457303)

  • 1. CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein.
    Egorova TV; Polikarpova AV; Vassilieva SG; Dzhenkova MA; Savchenko IM; Velyaev OA; Shmidt AA; Soldatov VO; Pokrovskii MV; Deykin AV; Bardina MV
    Mol Ther Methods Clin Dev; 2023 Sep; 30():161-180. PubMed ID: 37457303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.
    Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
    Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
    Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
    Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of early-onset cardiomyopathy in
    Rok M; Wong TWY; Maino E; Ahmed A; Yang G; Hyatt E; Lindsay K; Fatehi S; Marks R; Delgado-Olguín P; Ivakine EA; Cohn RD
    Mol Ther Methods Clin Dev; 2023 Sep; 30():246-258. PubMed ID: 37545481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy.
    Mollanoori H; Rahmati Y; Hassani B; Havasi Mehr M; Teimourian S
    Genes Dis; 2021 Mar; 8(2):146-156. PubMed ID: 33997161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
    Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN
    Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 13. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
    Lim KRQ; Yoon C; Yokota T
    J Pers Med; 2018 Nov; 8(4):. PubMed ID: 30477208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.
    Karri DR; Zhang Y; Chemello F; Min YL; Huang J; Kim J; Mammen PPA; Xu L; Liu N; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2022 Jun; 28():154-167. PubMed ID: 35402069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.
    Chai AC; Chemello F; Li H; Nishiyama T; Chen K; Zhang Y; Sánchez-Ortiz E; Alomar A; Xu L; Liu N; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2023 Jun; 32():522-535. PubMed ID: 37215149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional correction of dystrophin actin binding domain mutations by genome editing.
    Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.